We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ALLO market cap is 591.82M. The company's latest EPS is USD -1.9354 and P/E is -1.81.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 49k | 47k | 52k | 44k | 43k |
| Operating Income | -82.49M | -96.37M | -99.07M | -80.52M | -62.98M |
| Net Income | -83.15M | -94.85M | -98.7M | -77.99M | -61.32M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 38.49M | 243k | 95k |
| Operating Income | -202.01M | -258.24M | -255.79M | -335.45M | -314.49M |
| Net Income | -184.59M | -250.22M | -257.01M | -332.63M | -327.27M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 887.57M | 817.08M | 746.87M | 770.97M | 712.33M |
| Total Liabilities | 147.61M | 151.21M | 154.61M | 148.07M | 129.22M |
| Total Equity | 739.96M | 665.87M | 592.26M | 622.91M | 583.1M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 717.8M | 1.23B | 1.04B | 817.08M | 642.84M |
| Total Liabilities | 88.78M | 148.21M | 122.23M | 151.21M | 130.6M |
| Total Equity | 629.02M | 1.08B | 916.41M | 665.87M | 512.23M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -158.42M | -220.52M | -66.64M | -128.5M | -184.03M |
| Investing | 56.56M | 106.16M | 112.94M | 130.1M | 95.83M |
| Financing | 2.9M | 2.95M | 1.73M | 91.26M | 95.54M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -137.35M | -115.09M | -184.81M | -220.52M | -237.73M |
| Investing | 164.08M | -505.12M | 163.66M | 106.16M | 163.29M |
| Financing | 58.96M | 633.59M | 11.96M | 2.95M | 95.7M |
| Market Cap | 591.82M |
| Price to Earnings Ratio | -1.81 |
| Price to Sales Ratio | 5.83k |
| Price to Cash Ratio | 7.12 |
| Price to Book Ratio | 1.16 |
| Dividend Yield | - |
| Shares Outstanding | 169.09M |
| Average Volume (1 week) | 2.06M |
| Average Volume (1 Month) | 1.68M |
| 52 Week Change | -30.56% |
| 52 Week High | 6.89 |
| 52 Week Low | 2.23 |
| Spread (Intraday) | 0.02 (0.57%) |
| Company Name | Allogene Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.allogene.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
